Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan.
School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
Pharmacoeconomics. 2019 Mar;37(3):301-331. doi: 10.1007/s40273-018-0746-y.
The economic burden of renal cell carcinoma (RCC) had been reported to be significant in a previous review published in 2011.
The objective of this study was to perform an updated review by synthesizing economic studies related to the treatment of RCC that have been published since the previous review.
We performed a literature search in PubMed, EMBASE, and the Cochrane Library, covering English-language studies published between June 2010 and August 2018. We categorized these articles by type of analyses [cost-effectiveness analysis (CEA), cost analysis, and cost of illness (COI)] and treatment setting (cancer status and treatment), discussed findings from these articles, and synthesized information from each article in summary tables.
We identified 52 studies from 2317 abstracts/titles deemed relevant from the initial search, including 21 CEA, 23 cost analysis, and 8 COI studies. For localized RCC, costs were found to be positively associated with the aggressiveness of the local treatment. For metastatic RCC (mRCC), pazopanib was reported to be cost effective in the first-line setting. We also found that the economic burden of RCC has increased over time.
RCC continues to impose a substantial economic burden to the healthcare system. Despite the large number of treatment alternatives now available for advanced RCC, the cost effectiveness and budgetary impact of many new agents remain unknown and warrant greater attention in future research.
2011 年发表的一篇综述曾报道，肾细胞癌（RCC）的经济负担巨大。
本研究旨在对 2011 年综述发表后已发表的与 RCC 治疗相关的经济研究进行综合评价。
我们在 PubMed、EMBASE 和 Cochrane 图书馆中进行了文献检索，检索了 2010 年 6 月至 2018 年 8 月发表的英文研究。我们根据分析类型（成本效益分析（CEA）、成本分析和疾病成本（COI））和治疗环境（癌症状态和治疗）对这些文章进行分类，讨论了这些文章的结果，并在总结表中综合了每篇文章的信息。
我们从最初搜索中确定了 2317 篇摘要/标题中有 52 篇相关研究，包括 21 篇 CEA、23 篇成本分析和 8 篇 COI 研究。对于局限性 RCC，成本与局部治疗的侵袭性呈正相关。对于转移性 RCC（mRCC），帕唑帕尼在一线治疗中被报道具有成本效益。我们还发现，RCC 的经济负担随着时间的推移而增加。
RCC 继续给医疗保健系统带来巨大的经济负担。尽管目前有许多治疗晚期 RCC 的替代方法，但许多新药物的成本效益和预算影响仍然未知，值得在未来的研究中进一步关注。
